{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:51:18Z","timestamp":1789829478644,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T00:00:00Z","timestamp":1710547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of Nanjing University of Chinese Medicine","award":["No. XZR2023075"],"award-info":[{"award-number":["No. XZR2023075"]}]},{"name":"The Hospital Management Research of Nanjing Drum Tower Hospital","award":["No. NDYGN2023002"],"award-info":[{"award-number":["No. NDYGN2023002"]}]},{"name":"Medical Research of Jiangsu Health Committee","award":["No. H2023068"],"award-info":[{"award-number":["No. H2023068"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10753-024-02003-8","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T02:02:11Z","timestamp":1710554531000},"page":"1699-1705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy"],"prefix":"10.1007","volume":"47","author":[{"given":"Sihui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,16]]},"reference":[{"issue":"1","key":"2003_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley, P.J., M. Bachini, S.I. Ilyas, et al. 2021. Cholangiocarcinoma. Nature Reviews Disease Primers 7 (1): 65. https:\/\/doi.org\/10.1038\/s41572-021-00300-2.","journal-title":"Nature Reviews Disease Primers"},{"issue":"4","key":"2003_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jamcollsurg.2013.05.021","volume":"217","author":"RM Dodson","year":"2013","unstructured":"Dodson, R.M., M.J. Weiss, D. Cosgrove, et al. 2013. Intrahepatic cholangiocarcinoma: management options and emerging therapies. Journal of the American College of Surgeons 217 (4): 736-750.e4. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2013.05.021.","journal-title":"Journal of the American College of Surgeons"},{"issue":"4","key":"2003_CR3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/00000658-200110000-00010","volume":"234","author":"WR Jarnagin","year":"2001","unstructured":"Jarnagin, W.R., Y. Fong, R.P. DeMatteo, et al. 2001. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Annals of Surgery 234 (4): 507\u201317. https:\/\/doi.org\/10.1097\/00000658-200110000-00010.","journal-title":"Annals of Surgery"},{"issue":"6","key":"2003_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/archsurg.2011.116","volume":"146","author":"JC Hong","year":"2011","unstructured":"Hong, J.C., C.M. Jones, J.P. Duffy, et al. 2011. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Archives of Surgery 146 (6): 683\u20139. https:\/\/doi.org\/10.1001\/archsurg.2011.116.","journal-title":"Archives of Surgery"},{"issue":"6230","key":"2003_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher, T.N., and R.D. Schreiber. 2015. Neoantigens in cancer immunotherapy. Science 348 (6230): 69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science"},{"issue":"7662","key":"2003_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U., E. Derhovanessian, M. Miller, et al. 2017. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547 (7662): 222\u2013226.\u00a0https:\/\/doi.org\/10.1038\/nature23003.","journal-title":"Nature"},{"issue":"2","key":"2003_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P.A., S. Hu-Lieskovan, B. Chmielowski, et al. 2020. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183 (2): 347-362.e24.\u00a0https:\/\/doi.org\/10.1016\/j.cell.2020.08.053.","journal-title":"Cell"},{"key":"2003_CR8","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-040210-162544","volume":"63","author":"AZ Wang","year":"2012","unstructured":"Wang, A.Z., R. Langer, and O.C. Farokhzad. 2012. Nanoparticle delivery of cancer drugs. Annual Review of Medicine 63: 185\u201398. https:\/\/doi.org\/10.1146\/annurev-med-040210-162544.","journal-title":"Annual Review of Medicine"},{"key":"2003_CR9","doi-asserted-by":"publisher","first-page":"799026","DOI":"10.3389\/fimmu.2022.799026","volume":"13","author":"J Shao","year":"2022","unstructured":"Shao, J., Q. Liu, J. Shen, et al. 2022. Advanced pancreatic cancer patient benefit from personalized neoantigen nanovaccine based immunotherapy: a case report. Fronties in Immunology 13: 799026.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2022.799026.","journal-title":"Fronties in Immunology"},{"issue":"8","key":"2003_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/hpb.12441","volume":"17","author":"SM Weber","year":"2015","unstructured":"Weber, S.M., D. Ribero, E.M. O\u2019Reilly, N. Kokudo, M. Miyazaki, and T.M. Pawlik. 2015. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford) 17 (8): 669\u201380. https:\/\/doi.org\/10.1111\/hpb.12441.","journal-title":"HPB (Oxford)"},{"issue":"6","key":"2003_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.surg.2012.12.005","volume":"153","author":"O Hyder","year":"2013","unstructured":"Hyder, O., I. Hatzaras, G.C. Sotiropoulos, et al. 2013. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153 (6): 811\u20138. https:\/\/doi.org\/10.1016\/j.surg.2012.12.005.","journal-title":"Surgery"},{"issue":"5","key":"2003_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(18)30915-x","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose, J.N., R.P. Fox, D.H. Palmer, et al. 2019. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology 20 (5): 663\u2013673. https:\/\/doi.org\/10.1016\/s1470-2045(18)30915-x.","journal-title":"The Lancet Oncology"},{"issue":"5","key":"2003_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A., and G. Brandi. 2021. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterolgy & Hepatology 15 (5): 483\u2013485. https:\/\/doi.org\/10.1080\/17474124.2021.1864325.","journal-title":"Expert Review of Gastroenterolgy & Hepatology"},{"issue":"5","key":"2003_CR14","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan, M.K., M.A. Postow, and J.D. Wolchok. 2016. Targeting T cell co-receptors for cancer therapy. Immunity 44 (5): 1069\u201378. https:\/\/doi.org\/10.1016\/j.immuni.2016.04.023.","journal-title":"Immunity"},{"issue":"4","key":"2003_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos, A. 2016. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nature Review Drug Discovery 15 (4): 235\u201347. https:\/\/doi.org\/10.1038\/nrd.2015.35.","journal-title":"Nature Review Drug Discovery"},{"key":"2003_CR16","doi-asserted-by":"publisher","DOI":"10.14800\/ccm.677","author":"AR Kwilas","year":"2015","unstructured":"Kwilas, A.R., R.N. Donahue, K.Y. Tsang, and J.W. Hodge. 2015. mmune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy. Cancer Cell Microenvironment. https:\/\/doi.org\/10.14800\/ccm.677.","journal-title":"Cancer Cell Microenvironment"},{"issue":"2","key":"2003_CR17","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato, Y., K. Tabata, T. Kimura, et al. 2019. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One 14 (2).","journal-title":"PLoS One"},{"issue":"11","key":"2003_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/jco.19.01598","volume":"38","author":"MH Taylor","year":"2020","unstructured":"Taylor, M.H., C.H. Lee, V. Makker, et al. 2020. Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. Journal of Clinical Oncology 38 (11): 1154\u20131163. https:\/\/doi.org\/10.1200\/jco.19.01598.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"2003_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41698-022-00320-5","volume":"6","author":"ME Lidsky","year":"2022","unstructured":"Lidsky, M.E., Z. Wang, M. Lu, et al. 2022. Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies. NPJ\u00a0 Precision Oncology 6 (1): 75. https:\/\/doi.org\/10.1038\/s41698-022-00320-5.","journal-title":"NPJ\u00a0 Precision Oncology"},{"issue":"9","key":"2003_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","volume":"80","author":"SM Hoy","year":"2020","unstructured":"Hoy, S.M. 2020. Pemigatinib: first approval. Drugs 80 (9): 923\u2013929. https:\/\/doi.org\/10.1007\/s40265-020-01330-y.","journal-title":"Drugs"},{"issue":"5","key":"2003_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/17474124.2021.1911646","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A., A.D. Ricci, G. Frega, A. Di Federico, and G. Brandi. 2021. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. Expert of Review Gastroenterology & Hepatology 15 (5): 567\u2013574. https:\/\/doi.org\/10.1080\/17474124.2021.1911646.","journal-title":"Expert of Review Gastroenterology & Hepatology"},{"issue":"5","key":"2003_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/s1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G.K., V. Sahai, A. Hollebecque, et al. 2020. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. The Lancet Oncology 21 (5): 671\u2013684. https:\/\/doi.org\/10.1016\/s1470-2045(20)30109-1.","journal-title":"The Lancet Oncology"},{"issue":"4","key":"2003_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., B. Schr\u00f6rs, M. L\u00f6wer, \u00d6. T\u00fcreci, and U. Sahin. 2022. Identification of neoantigens for individualized therapeutic cancer vaccines. Nature reviews Drug discovery 21 (4): 261\u2013282. https:\/\/doi.org\/10.1038\/s41573-021-00387-y.","journal-title":"Nature reviews Drug discovery"},{"issue":"7528","key":"2003_CR24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","volume":"515","author":"MM Gubin","year":"2014","unstructured":"Gubin, M.M., X. Zhang, H. Schuster, et al. 2014. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (7528): 577\u201381. https:\/\/doi.org\/10.1038\/nature13988.","journal-title":"Nature"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-024-02003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-024-02003-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-024-02003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T03:08:31Z","timestamp":1731035311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-024-02003-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,16]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1007\/s10753-024-02003-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3687413\/v1","asserted-by":"object"}]},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,16]]},"assertion":[{"value":"30 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients\/participants provided written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}